Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Purpose
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
Conditions
- Breast Cancer
- Hereditary Breast and Ovarian Cancer
Eligibility
- Eligible Ages
- All ages
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
include: Triple Negative Breast Cancer - ER/PR <10% and HER negative per current ASCO/CAP guidelines - Stages I-IV - Any age at diagnosis - Patient must be within 5 years of diagnosis - Eligible regardless of genetic testing status - Genetic testing recommended for patients meeting NCCN and Medicare guidelines AND/OR Germline mutation Carriers - Patients with deleterious or uncertain mutations in HBOC genes (BRCA, PTEN, P53, -PALB2 etc) are eligible regardless of type/site of cancer - Healthy patients harboring mutations also eligible - There is no time limit from the time of diagnosis of cancer and enrollment. - Eligible regardless of personal history of cancer
Exclusion Criteria
include: Triple Negative Breast Cancer -Patient is not within five years of diagnosis Germline mutation Carriers: -Patient only carries a HBOC mutation that is classified as "polymorphism" of "favor polymorphism"
Study Design
- Phase
- Study Type
- Observational [Patient Registry]
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Triple Negative Breast Cancer patients | No intervention | |
| Germline HBOC Mutation Carriers | No intervention |
Recruiting Locations
Westwood, Kansas 66205
More Details
- Status
- Recruiting
- Sponsor
- University of Kansas Medical Center
Detailed Description
This study is being done to collect cancer-related information from patients with triple negative breast cancer and patients with hereditary genetic mutations. This information will help us better understand the link between genetic changes and cancer outcome in patients with triple negative breast cancer.